Different roles of CXCR1 and CXCR2 in HTLV-1 carriers and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients.
CXCR1
CXCR2
HAM/TSP
HTLV-1
Journal
Medical microbiology and immunology
ISSN: 1432-1831
Titre abrégé: Med Microbiol Immunol
Pays: Germany
ID NLM: 0314524
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
06
11
2017
accepted:
09
10
2018
pubmed:
21
10
2018
medline:
11
1
2020
entrez:
21
10
2018
Statut:
ppublish
Résumé
One of the prominent features of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is the excessive recruitment of leukocytes to the central nervous system (CNS), which leads to an inflammatory response-with chemokines and their receptors playing the main role in this recruitment. The aim of the study was to examine the relation of CXCR1 and CXCR2, both of which are involved in the trafficking of lymphocytes into the CNS, with the outcome of HTLV-1 infection. The mRNA levels of CXCR1 and CXCR2 were examined in peripheral blood mononuclear cells (PBMCs) of HAM/TSP patients, HTLV-1 asymptomatic carriers (ACs), and healthy controls (HCs). Furthermore, the frequency of CD4
Identifiants
pubmed: 30341468
doi: 10.1007/s00430-018-0568-8
pii: 10.1007/s00430-018-0568-8
doi:
Substances chimiques
CXCR2 protein, human
0
Receptors, Interleukin-8A
0
Receptors, Interleukin-8B
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
641-650Références
Curr Opin Immunol. 2000 Aug;12(4):397-402
pubmed: 10899027
J Immunol. 2002 Aug 1;169(3):1550-5
pubmed: 12133983
Blood. 2003 Apr 15;101(8):3074-81
pubmed: 12480698
Nihon Rinsho. 1992 Aug;50(8):1816-20
pubmed: 1433973
J Immunol. 2004 Feb 1;172(3):1735-43
pubmed: 14734756
J Leukoc Biol. 2004 Aug;76(2):441-50
pubmed: 15155777
Brain. 2005 May;128(Pt 5):1003-15
pubmed: 15774504
Glia. 2006 Jan 1;53(1):24-31
pubmed: 16086366
N Engl J Med. 2006 Feb 9;354(6):610-21
pubmed: 16467548
Virology. 2007 Feb 5;358(1):98-108
pubmed: 16996102
Eur J Immunol. 2007 Jan;37(1):54-65
pubmed: 17171755
Lancet Infect Dis. 2007 Apr;7(4):266-81
pubmed: 17376384
J Clin Immunol. 2008 Mar;28(2):122-30
pubmed: 17960472
Trends Immunol. 2008 Jan;29(1):4-11
pubmed: 18042431
J Exp Med. 2008 Apr 14;205(4):811-23
pubmed: 18347102
Inflamm Allergy Drug Targets. 2008 Jun;7(2):98-107
pubmed: 18691139
Nat Immunol. 2008 Sep;9(9):949-52
pubmed: 18711431
Am J Pathol. 2009 Jan;174(1):164-76
pubmed: 19095949
Exp Neurol. 2009 Nov;220(1):44-56
pubmed: 19616545
PLoS Pathog. 2009 Nov;5(11):e1000648
pubmed: 19893623
J Cereb Blood Flow Metab. 2010 Mar;30(3):459-73
pubmed: 19904283
Exp Neurol. 2010 Sep;225(1):9-17
pubmed: 19961850
Nat Neurosci. 2010 Mar;13(3):319-26
pubmed: 20154684
J Neuroimmune Pharmacol. 2010 Sep;5(3):310-25
pubmed: 20437106
Neuropathology. 2010 Oct;30(5):480-5
pubmed: 20573027
PLoS One. 2010 Jun 28;5(6):e11340
pubmed: 20596532
J Neurosci. 2010 Jul 7;30(27):9074-83
pubmed: 20610741
FEBS Lett. 2011 Dec 1;585(23):3730-7
pubmed: 21539842
J Clin Virol. 2011 Nov;52(3):172-6
pubmed: 21840754
J Neuroimmunol. 2012 Sep 15;250(1-2):87-93
pubmed: 22727800
Immunol Invest. 2013;42(8):737-48
pubmed: 23876169
Iran J Basic Med Sci. 2013 Mar;16(3):268-72
pubmed: 24470875
J Neuropathol Exp Neurol. 2015 Jan;74(1):2-14
pubmed: 25470342
Biomarkers. 2015;20(6-7):502-12
pubmed: 26474234
J Med Virol. 2016 Aug;88(8):1438-47
pubmed: 26800845
Theranostics. 2017 Apr 7;7(6):1543-1588
pubmed: 28529637
J Immunol. 1994 Dec 15;153(12):5682-8
pubmed: 7527448
J Immunol. 1995 Sep 1;155(5):2587-94
pubmed: 7650389
Med Hypotheses. 1993 Dec;41(6):542-7
pubmed: 8183132
J Immunol. 1997 Feb 1;158(3):1361-9
pubmed: 9013980
Am J Pathol. 1997 Feb;150(2):617-30
pubmed: 9033275
Leuk Lymphoma. 1996 May;21(5-6):443-7
pubmed: 9172809
J Biol Chem. 1998 Sep 11;273(37):23830-6
pubmed: 9726994
Cancer Res. 1998 Sep 1;58(17):3993-4000
pubmed: 9731513
J Immunol. 1999 Feb 1;162(3):1765-71
pubmed: 9973440